1. Home
  2. MREO vs ASA Comparison

MREO vs ASA Comparison

Compare MREO & ASA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • ASA
  • Stock Information
  • Founded
  • MREO 2015
  • ASA 1958
  • Country
  • MREO United Kingdom
  • ASA United States
  • Employees
  • MREO N/A
  • ASA N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • ASA Precious Metals
  • Sector
  • MREO Health Care
  • ASA Industrials
  • Exchange
  • MREO Nasdaq
  • ASA Nasdaq
  • Market Cap
  • MREO 438.8M
  • ASA 622.9M
  • IPO Year
  • MREO N/A
  • ASA N/A
  • Fundamental
  • Price
  • MREO $1.67
  • ASA $32.81
  • Analyst Decision
  • MREO Strong Buy
  • ASA
  • Analyst Count
  • MREO 5
  • ASA 0
  • Target Price
  • MREO $7.20
  • ASA N/A
  • AVG Volume (30 Days)
  • MREO 3.8M
  • ASA 57.7K
  • Earning Date
  • MREO 08-12-2025
  • ASA 07-22-2025
  • Dividend Yield
  • MREO N/A
  • ASA 0.12%
  • EPS Growth
  • MREO N/A
  • ASA N/A
  • EPS
  • MREO N/A
  • ASA 11.67
  • Revenue
  • MREO N/A
  • ASA $3,557,386.00
  • Revenue This Year
  • MREO N/A
  • ASA N/A
  • Revenue Next Year
  • MREO $52.34
  • ASA N/A
  • P/E Ratio
  • MREO N/A
  • ASA $2.79
  • Revenue Growth
  • MREO N/A
  • ASA 45.39
  • 52 Week Low
  • MREO $1.57
  • ASA $17.42
  • 52 Week High
  • MREO $5.02
  • ASA $35.00
  • Technical
  • Relative Strength Index (RSI)
  • MREO 24.94
  • ASA 55.04
  • Support Level
  • MREO $2.77
  • ASA $31.06
  • Resistance Level
  • MREO $3.05
  • ASA $32.65
  • Average True Range (ATR)
  • MREO 0.18
  • ASA 0.98
  • MACD
  • MREO -0.15
  • ASA -0.01
  • Stochastic Oscillator
  • MREO 0.34
  • ASA 84.10

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About ASA ASA Gold and Precious Metals Limited

ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.

Share on Social Networks: